Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort-Reference-Cited by-同舟云学术

Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort

Published:2015-02-12 Issue:4 Volume:24 Page:406-413
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Abbas Sascha¹,Ihle Peter¹,Harder Sebastian²,Schubert Ingrid¹

Affiliation:

1. PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy; University of Cologne; Cologne Germany

2. Institute of Clinical Pharmacology; University Hospital Frankfurt am Main; Frankfurt am Main Germany

Funder

Federal Association of the AOK

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference40 articles.

1. Heart failure epidemiology: European perspective;Guha;Curr Cardiol Rev,2013

2. Epidemiology and risk profile of heart failure;Bui;Nat Rev Cardiol,2011

3. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators;Pitt;N Engl J Med,1999

4. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction;Pitt;N Engl J Med,2003

5. Eplerenone in patients with systolic heart failure and mild symptoms;Zannad;N Engl J Med,2011

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Definition of Polypharmacy in Heart Failure: A Scoping Review of the Literature;Cardiology Research;2024-04

2. Changes in serum potassium with concomitant administration of renin-angiotensin system agents and potassium-sparing diuretics: U.S. cohort study using electronic health record data;JAPhA Pharmacotherapy;2024-01

3. New Therapy Update Aprocitentan: An Endothelin Receptor Antagonist for the Treatment of Drug-Resistant Systemic Hypertension;Cardiology in Review;2023-08-02

4. Aprocitentan: A new development of resistant hypertension;The Journal of Clinical Hypertension;2023-06-19

5. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies;BMJ Open;2022-06